Connect with us

Hi, what are you looking for?

Thursday, Jun 1, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Clinical trial in UK to look at medical cannabis as treatment for long Covid

About 1.3M people in the UK have long Covid

Clinical trial in UK to look at medical cannabis as treatment for long Covid
Image by Filipe Esquivel Reed via Wikimedia Commons

Since cannabis is already used to alleviate symptoms similar to long Covid, an Australian company will be starting clinical trials to see if medical pot can be used as a treatment for the condition.

On Monday, cannabis-centric healthcare company Bod Australia Limited. (ASX: BOD) said it received authorization from U.K. regulators to immediately start a six-month clinical trial on the effectiveness of medical cannabis for long Covid. Bod will work with the independent scientific body Drug Science UK for the clinical trial.

“While there aren’t any existing treatments for long Covid, our medicinal cannabis products have been used to treat and alleviate a number of similar conditions,” Bod CEO Jo Patterson says. “We anticipate that this clinical trial will provide us with great insight into its potential to treat long Covid and build on the body of evidence for the use of cannabis-based medicines, in place of other pharmaceuticals.”

If the trial produces successful results, Bod says it plans to commercialize its product that treats the disease.

Read more: More studies are showing how cannabinoids help fight Covid


Long Covid is a condition that refers to persistent or new symptoms after an initial Covid-19 infection. There’s a wide range of symptoms, including shortness of breath, chronic pain, anxiety, sleep disturbances and fatigue.

The World Health Organization notes that symptoms may fluctuate or relapse over time, and can have a general impact on everyday functioning.

Recent estimates say about 1.3 million people in the U.K. have long Covid. Most (70 per cent) reported catching the virus 12 weeks before, and around 40 per cent said they first got the illness at least a year prior.

For the clinical trials, 30 participants over the age of 18 suffering from long Covid will be recruited to take daily doses of Bod’s medicinal cannabis product, MediCabilis 5%, for six months.

Bottle of Bod Australia's MediCabilis 5% next to a syringe

MediCablis products are currently prescribed to patients with conditions including chronic pain, anxiety and sleep disorders. Image via Bod Pharmaceuticals

Participants will self-report their symptoms on a daily and monthly basis through a smartphone app. Those results will determine the feasibility and safety of the medical cannabis product as a treatment.

Bod says a trial protocol has been finalized and an ethics approval secured, while patient recruitment is underway.

Cannabis and Covid headlines have cycled through newsfeeds following a recent lab study showing that cannabinoids can block entry of the virus into cells.

Read more: Weed impedes entry of Covid-19 into cells: study


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Kathryn Tindale on Twitter



  1. Elaine

    January 25, 2022 at 7:06 am

    How can I get on this trial I have been suffering pains for 6 months I believe its long covid the Dr say neuropathic ms I have very high vitamin b levels

  2. Budd

    January 26, 2022 at 3:55 pm

    How do I participate in the Trial please? I am currently suffering from no smell or taste and continual congestion, since before Christmas. I also feel that it is starting to effect my mental health.
    I haven’t been prescribed anything but have been using a OTC nasal spray that seems to only last a few hours, I have also been looking and reading about my symptoms and that I would be interested in taking part.
    Kind Regards,

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


The company will be supporting the cancer and patient care conference ONCOWELLNESS


The company received its fifth GMP certification from the European Union, Colombia and Brazil


The company will be supplying Germany's Sanity Group with high-grade medical cannabis flower


The company aims to start selling TGOD products starting in in Q4 this year